Literature DB >> 26181354

Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain.

Helena A Yu1, Shaozhou K Tian2, Alexander E Drilon1, Laetitia Borsu2, Gregory J Riely1, Maria E Arcila2, Marc Ladanyi3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26181354      PMCID： PMC4665629          DOI： 10.1001/jamaoncol.2015.1066

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  5 in total

1.  Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.

Authors:  Jennifer A Woyach; Richard R Furman; Ta-Ming Liu; Hatice Gulcin Ozer; Marc Zapatka; Amy S Ruppert; Ling Xue; Daniel Hsieh-Hsin Li; Susanne M Steggerda; Matthias Versele; Sandeep S Dave; Jenny Zhang; Ayse Selen Yilmaz; Samantha M Jaglowski; Kristie A Blum; Arletta Lozanski; Gerard Lozanski; Danelle F James; Jacqueline C Barrientos; Peter Lichter; Stephan Stilgenbauer; Joseph J Buggy; Betty Y Chang; Amy J Johnson; John C Byrd
Journal:  N Engl J Med       Date:  2014-05-28       Impact factor: 91.245

2.  Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Authors:  Helena A Yu; Maria E Arcila; Natasha Rekhtman; Camelia S Sima; Maureen F Zakowski; William Pao; Mark G Kris; Vincent A Miller; Marc Ladanyi; Gregory J Riely
Journal:  Clin Cancer Res       Date:  2013-03-07       Impact factor: 12.531

3.  Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies.

Authors:  Zhiwei Yu; Titus J Boggon; Susumu Kobayashi; Cheng Jin; Patrick C Ma; Afshin Dowlati; Jeffrey A Kern; Daniel G Tenen; Balázs Halmos
Journal:  Cancer Res       Date:  2007-11-01       Impact factor: 12.701

4.  Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance.

Authors:  Phillip A Schwartz; Petr Kuzmic; James Solowiej; Simon Bergqvist; Ben Bolanos; Chau Almaden; Asako Nagata; Kevin Ryan; Junli Feng; Deepak Dalvie; John C Kath; Meirong Xu; Revati Wani; Brion William Murray
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-17       Impact factor: 11.205

5.  Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.

Authors:  Wenjun Zhou; Dalia Ercan; Liang Chen; Cai-Hong Yun; Danan Li; Marzia Capelletti; Alexis B Cortot; Lucian Chirieac; Roxana E Iacob; Robert Padera; John R Engen; Kwok-Kin Wong; Michael J Eck; Nathanael S Gray; Pasi A Jänne
Journal:  Nature       Date:  2009-12-24       Impact factor: 49.962
  5 in total
  80 in total

1.  Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.

Authors:  Justin F Gainor; Leila Dardaei; Satoshi Yoda; Luc Friboulet; Ignaty Leshchiner; Ryohei Katayama; Ibiayi Dagogo-Jack; Shirish Gadgeel; Katherine Schultz; Manrose Singh; Emily Chin; Melissa Parks; Dana Lee; Richard H DiCecca; Elizabeth Lockerman; Tiffany Huynh; Jennifer Logan; Lauren L Ritterhouse; Long P Le; Ashok Muniappan; Subba Digumarthy; Colleen Channick; Colleen Keyes; Gad Getz; Dora Dias-Santagata; Rebecca S Heist; Jochen Lennerz; Lecia V Sequist; Cyril H Benes; A John Iafrate; Mari Mino-Kenudson; Jeffrey A Engelman; Alice T Shaw
Journal:  Cancer Discov       Date:  2016-07-18       Impact factor: 39.397

2.  Superior Efficacy and Selectivity of Novel Small-Molecule Kinase Inhibitors of T790M-Mutant EGFR in Preclinical Models of Lung Cancer.

Authors:  Jin Kyung Rho; In Yong Lee; Yun Jung Choi; Chang-Min Choi; Jae-Young Hur; Jong Sung Koh; Jaekyoo Lee; Byung-Chul Suh; Ho-Juhn Song; Paresh Salgaonkar; Jungmi Lee; Jaesang Lee; Dong Sik Jung; Sang-Yeob Kim; Dong-Cheol Woo; In-Jeoung Baek; Joo-Yong Lee; Chang Hoon Ha; Young Hoon Sung; Jeong Kon Kim; Woo Sung Kim; Joon Seon Song; Cheol Hyeon Kim; Trever G Bivona; Jae Cheol Lee
Journal:  Cancer Res       Date:  2017-01-12       Impact factor: 12.701

Review 3.  Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance.

Authors:  Roberta Minari; Paola Bordi; Marcello Tiseo
Journal:  Transl Lung Cancer Res       Date:  2016-12

4.  Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers.

Authors:  H A Yu; C Sima; D Feldman; L L Liu; B Vaitheesvaran; J Cross; C M Rudin; M G Kris; W Pao; F Michor; G J Riely
Journal:  Ann Oncol       Date:  2017-02-01       Impact factor: 32.976

Review 5.  Polytherapy and Targeted Cancer Drug Resistance.

Authors:  Nilanjana Chatterjee; Trever G Bivona
Journal:  Trends Cancer       Date:  2019-02-26

6.  Extending the curve: survival of EGFR-mutated lung cancer patients in the 21st century.

Authors:  Feliciano Barrón; Zyanya Lucia Zatarain-Barrón; Andrés F Cardona; Oscar Arrieta
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

7.  Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma.

Authors:  Nicole L Michmerhuizen; Elizabeth Leonard; Chloe Matovina; Micah Harris; Gabrielle Herbst; Aditi Kulkarni; Jingyi Zhai; Hui Jiang; Thomas E Carey; J Chad Brenner
Journal:  Mol Pharmacol       Date:  2019-03-11       Impact factor: 4.436

8.  Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort.

Authors:  Stephen R Fairclough; Lesli A Kiedrowski; Jessica J Lin; Ori Zelichov; Gabi Tarcic; Thomas E Stinchcombe; Justin I Odegaard; Richard B Lanman; Alice T Shaw; Rebecca J Nagy
Journal:  Exp Hematol Oncol       Date:  2019-10-11

Review 9.  Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.

Authors:  Solange Peters; Stefan Zimmermann
Journal:  Curr Treat Options Oncol       Date:  2018-05-28

Review 10.  Molecular mechanisms of therapy resistance in solid tumors: chasing "moving" targets.

Authors:  Laura J Tafe
Journal:  Virchows Arch       Date:  2017-03-10       Impact factor: 4.064
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.